GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
Adds context in paragraphs 2-5
Nov 22 (Reuters) -GSK GSK.L said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK's RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagious virus that affects the lungs and breathing passages.
The approval in Japan will be a shot in the arm for GSK, which has slashed its 2024 vaccine sales forecast twice this year.
The nod for expanded use of Arexvy in Japan comes after GSK last month flagged that its vaccine sales would fall this year, partly due to declining Shingrix sales in the U.S. and China and a weaker-than-expected third quarter for RSV sales in the U.S.
GSK's RSV vaccine has been approved for adults aged between 50 and 59 at increased risk in 35 countries, the company said in a statement.
Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Abinaya Vijayaraghavan
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
